表紙
市場調查報告書

血小板反應蛋白基序5的解聚素及金屬蛋白酶:開發中產品分析

A Disintegrin And Metalloproteinase With Thrombospondin Motifs 5 - Pipeline Review, H2 2019

出版商 Global Markets Direct 商品編碼 371019
出版日期 內容資訊 英文 65 Pages
訂單完成後即時交付
價格
Back to Top
血小板反應蛋白基序5的解聚素及金屬蛋白酶:開發中產品分析 A Disintegrin And Metalloproteinase With Thrombospondin Motifs 5 - Pipeline Review, H2 2019
出版日期: 2019年12月27日內容資訊: 英文 65 Pages
簡介

本報告提供以血小板反應蛋白基序5的解聚素及金屬蛋白酶為標的之治療藥開發平台現狀及最新更新的各開發階段比較分析,提供您加上最新的新聞和發表之企業和研究機關開發中的治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

血小板反應蛋白基序5的解聚素及金屬蛋白酶 概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:不同症狀

開發中產品概況

  • 後期階段的產品
  • 初期階段的產品

企業開發中的產品

治療藥的評估

  • 單劑/並用治療藥的情況
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

治療藥的開發企業

  • 旭化成製藥
  • GlaxoSmithKline Plc
  • Oscotec Inc.
  • Paradigm Biopharmaceuticals Limited

藥物簡介

暫停中的計劃

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC2191TDB

Summary

According to the recently published report 'A Disintegrin And Metalloproteinase With Thrombospondin Motifs 5 - Pipeline Review, H2 2019'; A Disintegrin And Metalloproteinase With Thrombospondin Motifs 5 (A Disintegrin And Metalloproteinase With Thrombospondin Motifs 11 or Aggrecanase 2 or ADMP2 or ADAMTS5 or EC 3.4.24.) pipeline Target constitutes close to 7 molecules.

A Disintegrin And Metalloproteinase With Thrombospondin Motifs 5 (A Disintegrin And Metalloproteinase With Thrombospondin Motifs 11 or Aggrecanase 2 or ADMP2 or ADAMTS5 or EC 3.4.24.) - A disintegrin and metalloproteinase with thrombospondin motifs 5 or ADAMTS5 is an enzyme encoded by the ADAMTS5 gene. It plays an important role in the destruction of aggrecan in arthritic diseases and in proteolytic processing mostly during the peri-implantation period.

The report 'A Disintegrin And Metalloproteinase With Thrombospondin Motifs 5 - Pipeline Review, H2 2019' outlays comprehensive information on the A Disintegrin And Metalloproteinase With Thrombospondin Motifs 5 (A Disintegrin And Metalloproteinase With Thrombospondin Motifs 11 or Aggrecanase 2 or ADMP2 or ADAMTS5 or EC 3.4.24.) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in A Disintegrin And Metalloproteinase With Thrombospondin Motifs 5 (A Disintegrin And Metalloproteinase With Thrombospondin Motifs 11 or Aggrecanase 2 or ADMP2 or ADAMTS5 or EC 3.4.24.) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I and Preclinical stages are 2, 1 and 4 respectively. Report covers products from therapy areas Musculoskeletal Disorders, Cardiovascular, Central Nervous System, Genetic Disorders, Infectious Disease and Respiratory which include indications Osteoarthritis, Knee Osteoarthritis, Allergic Asthma, Alphavirus Infections, Arthralgia (Joint Pain), Arthritis, Chikungunya Fever, Congestive Heart Failure (Heart Failure), Edema, Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) and Seasonal Allergic Rhinitis.

Scope

  • The report provides a snapshot of the global therapeutic landscape for A Disintegrin And Metalloproteinase With Thrombospondin Motifs 5 (A Disintegrin And Metalloproteinase With Thrombospondin Motifs 11 or Aggrecanase 2 or ADMP2 or ADAMTS5 or EC 3.4.24.)
  • The report reviews A Disintegrin And Metalloproteinase With Thrombospondin Motifs 5 (A Disintegrin And Metalloproteinase With Thrombospondin Motifs 11 or Aggrecanase 2 or ADMP2 or ADAMTS5 or EC 3.4.24.) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in A Disintegrin And Metalloproteinase With Thrombospondin Motifs 5 (A Disintegrin And Metalloproteinase With Thrombospondin Motifs 11 or Aggrecanase 2 or ADMP2 or ADAMTS5 or EC 3.4.24.) targeted therapeutics and enlists all their major and minor projects
  • The report assesses A Disintegrin And Metalloproteinase With Thrombospondin Motifs 5 (A Disintegrin And Metalloproteinase With Thrombospondin Motifs 11 or Aggrecanase 2 or ADMP2 or ADAMTS5 or EC 3.4.24.) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to A Disintegrin And Metalloproteinase With Thrombospondin Motifs 5 (A Disintegrin And Metalloproteinase With Thrombospondin Motifs 11 or Aggrecanase 2 or ADMP2 or ADAMTS5 or EC 3.4.24.) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for A Disintegrin And Metalloproteinase With Thrombospondin Motifs 5 (A Disintegrin And Metalloproteinase With Thrombospondin Motifs 11 or Aggrecanase 2 or ADMP2 or ADAMTS5 or EC 3.4.24.)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding A Disintegrin And Metalloproteinase With Thrombospondin Motifs 5 (A Disintegrin And Metalloproteinase With Thrombospondin Motifs 11 or Aggrecanase 2 or ADMP2 or ADAMTS5 or EC 3.4.24.) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • A Disintegrin And Metalloproteinase With Thrombospondin Motifs 5 (A Disintegrin And Metalloproteinase With Thrombospondin Motifs 11 or Aggrecanase 2 or ADMP2 or ADAMTS5 or EC 3.4.24.) - Overview
  • A Disintegrin And Metalloproteinase With Thrombospondin Motifs 5 (A Disintegrin And Metalloproteinase With Thrombospondin Motifs 11 or Aggrecanase 2 or ADMP2 or ADAMTS5 or EC 3.4.24.) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • A Disintegrin And Metalloproteinase With Thrombospondin Motifs 5 (A Disintegrin And Metalloproteinase With Thrombospondin Motifs 11 or Aggrecanase 2 or ADMP2 or ADAMTS5 or EC 3.4.24.) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • A Disintegrin And Metalloproteinase With Thrombospondin Motifs 5 (A Disintegrin And Metalloproteinase With Thrombospondin Motifs 11 or Aggrecanase 2 or ADMP2 or ADAMTS5 or EC 3.4.24.) - Companies Involved in Therapeutics Development
  • Eli Lilly and Co
  • Galapagos NV
  • GlaxoSmithKline Plc
  • Merck KGaA
  • Paradigm Biopharmaceuticals Ltd
  • Ribomic Inc
  • Rottapharm Biotech Srl
  • A Disintegrin And Metalloproteinase With Thrombospondin Motifs 5 (A Disintegrin And Metalloproteinase With Thrombospondin Motifs 11 or Aggrecanase 2 or ADMP2 or ADAMTS5 or EC 3.4.24.) - Drug Profiles
  • CRB-0017 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • GLPG-1972 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • GSK-2394002 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • M-6495 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • pentosan polysulfate sodium - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • RBM-010 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Inhibit ADAMTS4 and ADAMTS5 for Osteoarthritis - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • A Disintegrin And Metalloproteinase With Thrombospondin Motifs 5 (A Disintegrin And Metalloproteinase With Thrombospondin Motifs 11 or Aggrecanase 2 or ADMP2 or ADAMTS5 or EC 3.4.24.) - Dormant Products
  • A Disintegrin And Metalloproteinase With Thrombospondin Motifs 5 (A Disintegrin And Metalloproteinase With Thrombospondin Motifs 11 or Aggrecanase 2 or ADMP2 or ADAMTS5 or EC 3.4.24.) - Product Development Milestones
  • Featured News & Press Releases
  • Sep 30, 2019: Peer-reviewed publication confirms Paradigms ground-breaking discovery regarding new MOA for PPS
  • Sep 10, 2019: Paradigms first FDA IND is cleared within the 30-day review period
  • Aug 29, 2019: Paradigm discovers Zilosulo (iPPS) protects cartilage in knee osteoarthritis
  • Jun 11, 2019: Servier and Galapagos complete enrollment of global ROCCELLA Phase 2 clinical trial with GLPG1972/S201086 in knee osteoarthritis patients
  • Jun 04, 2019: Paradigm reports successful ross river phase 2a clinical trial
  • May 28, 2019: Paradigm reports positive RWE data for knee osteoarthritis therapeutic
  • Apr 16, 2019: Paradigm's knee osteoarthritis study meets secondary endpoints
  • Feb 14, 2019: Paradigm's orphan phase 2/3 clinical program progresses
  • Nov 27, 2018: Galapagos receives Fast Track designation from FDA for GLPG1972/S201086 in osteoarthritis
  • Nov 07, 2018: Paradigms Osteoarthritis treatment maintains more than 50% knee pain reduction
  • Sep 25, 2018: Galapagos doses first patient in Phase ll trial of GLPG1972/S201086
  • Sep 25, 2018: Paradigm consistently shows greater than 50% knee pain reduction
  • Aug 28, 2018: Paradigm's phase 2 a Ross River virus clinical trial recruitment finalised
  • Aug 15, 2018: Paradigm achieves 60% reduction in osteoarthritis pain
  • Aug 06, 2018: Paradigm achieves 100% recruitment in Phase 2b Osteoarthritis Trial
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H2 2019
  • Number of Products under Development by Therapy Areas, H2 2019
  • Number of Products under Development by Indication, H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Stage and Route of Administration, H2 2019
  • Number of Products by Stage and Molecule Type, H2 2019
  • Pipeline by Eli Lilly and Co, H2 2019
  • Pipeline by Galapagos NV, H2 2019
  • Pipeline by GlaxoSmithKline Plc, H2 2019
  • Pipeline by Merck KGaA, H2 2019
  • Pipeline by Paradigm Biopharmaceuticals Ltd, H2 2019
  • Pipeline by Ribomic Inc, H2 2019
  • Pipeline by Rottapharm Biotech Srl, H2 2019
  • Dormant Projects, H2 2019

List of Figures

  • Number of Products under Development by Stage of Development, H2 2019
  • Number of Products under Development by Therapy Areas, H2 2019
  • Number of Products under Development by Top 10 Indications, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Routes of Administration, H2 2019
  • Number of Products by Stage and Routes of Administration, H2 2019
  • Number of Products by Molecule Types, H2 2019
  • Number of Products by Stage and Molecule Types, H2 2019
Back to Top